Disease-specific quality indicators, guidelines and outcome measures in scleroderma

被引：0
作者：
Valentini, G.
Cerinic, M. Matucci
机构：
[1] Univ Naples 2, Unita Reumatol, Policlin, I-80131 Naples, Italy
[2] Univ Florence, Florence, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2007年 / 25卷 / 06期
关键词：
systemic sclerosis; quality of life; outcome measures;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The assessment of the patient with systemic sclerosis remains a challenge for the clinical investigator and the clinician. The measures used to assess the impact of the disease on the quality of life and the outcome measures,for both clinical practice and clinical research, including therapeutic trials, are presented and discussed, with emphasis on present limitations.
引用
收藏
页码：S159 / S162
页数：4
相关论文
共 43 条
[1]  
Boers M, 1998, J RHEUMATOL, V25, P198
[2]   Tumor necrosis factor-α inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis [J].
Bosello, S ;
De Santis, M ;
Tolusso, B ;
Zoli, A ;
Ferraccioli, G .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (12) :918-920
[3]  
Bryan C, 1999, ARTHRITIS RHEUM-US, V42, P2660, DOI 10.1002/1529-0131(199912)42:12<2660::AID-ANR23>3.0.CO
[4]  
2-N
[5]  
CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
[6]  
Clements PJ, 1999, ARTHRITIS RHEUM-US, V42, P2372, DOI 10.1002/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO
[7]  
2-J
[8]  
Clements PJ, 2001, ARTHRITIS RHEUM-US, V44, P653, DOI 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.3.CO
[9]  
2-H
[10]  
CUOMO G, UNPUB HLTH ASSESSMEN
12345